High-dose vitamin B3 is showing intriguing early promise as an addition to standard glioblastoma treatment, with 82% of patients in a small trial remaining progression-free after six months. Researchers believe niacin may help revive immune cells suppressed by the cancer, but larger studies are still needed to confirm the benefit and safety.

High-dose vitamin B3 is showing intriguing early promise as an addition to standard glioblastoma treatment, with 82% of patients in a small trial remaining progression-free after six months. Researchers believe niacin may help revive immune cells suppressed by the cancer, but larger studies are still needed to confirm the benefit and safety.